New clinical trial arm for the SCALLOP consortium
“Maximizing the power of proteomic clinical trial profiling for better, actionable insights – a new collaborative initiative from the SCALLOP consortium”
In this webinar, SCALLOP consortium founder, Anders Mälarstig describes a new initiative that aims to maximize the statistical power of early phase clinical trial data through a collaborative approach:
- Hear how SCALLOP studies over the past 4 years have identified correlative and causal protein biomarkers for common complex diseases.
- Learn how protein quantitative trait loci (pQTLs) identified via proteogenomic studies, combined with systematic Mendelian randomization analysis, can identify novel drug targets based on the confident assessment of causality in the diseases of interest.
- Hear about a new clinical trial arm for SCALLOP, a pre-competitive collaboration aimed at studying dynamic protein changes over time and increasing the statistical power of proteomic profiling data from phase I/II trials.
- Understand the value of this collaborative approach in overcoming the challenges of small sample sizes in early clinical trials, enabling new insights into the mechanism of action, safety endpoints, and response stratification for investigational new drugs.
